Opinion|Videos|September 9, 2024
JAK Inhibitors in Atopic Dermatitis
A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- A number of JAK inhibitors, both oral (abrocitinib, upadacitnib) and topical (ruxolitinib cream), are FDA approved for atopic dermatitis.
- How have JAK inhibitors evolved over the years?
- How have differences between JAK inhibitors led to differences in their safety and efficacy profiles?
Advertisement
Related to this article
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
Advertisement
Advertisement
Trending on HCPLive
1
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
5 Gastroenterology Headlines You Missed in September 2026
4
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
5